Clenbuterol ("Spiropent'): a long-acting bronchodilator

Curr Med Res Opin. 1982;8(2):113-9. doi: 10.1185/03007998209109766.

Abstract

Clenbuterol was compared to an aminophylline preparation in a double-blind crossover trial involving 47 patients with asthma and reversible airways obstruction. Following a 2-week control period, each drug was given for a 4-week period. The patients made daily records of the severity of symptoms and recorded PEFR morning and night. Both drugs produced a highly significant reduction in severity and duration of wheeze by day during the first 4 weeks, but only clenbuterol produced further significant reduction in these symptoms during the second 4 weeks. Only clenbuterol produced a significant reduction in the severity of wheeze at night. When clenbuterol was given first there was a significant increase in the mean PEFR both night and morning but no other significant changes with either drug at other periods. Combining the results from the two treatment groups showed a significant difference between them in favour of clenbuterol in respect of duration of daytime wheeze only (p less than 0.05).

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aminophylline / adverse effects
  • Aminophylline / therapeutic use
  • Asthma / drug therapy*
  • Clenbuterol / adverse effects
  • Clenbuterol / therapeutic use*
  • Clinical Trials as Topic
  • Double-Blind Method
  • Ethanolamines / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged

Substances

  • Ethanolamines
  • Aminophylline
  • Clenbuterol